GlassScriptPhysician profile
William J Gibbs
NPI 1881660959
$1,000.95
in general payments reported to CMS, 2019-2025
14 companies · $486 in 2025
The $486 reported for 2025 was more than what 78% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $285 · 2021: $17.24 · 2022: $69.73 · 2024: $143 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $287.66 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $215.62 | 2020-2022 | |
| Glaxosmithkline, LLC. | $128.22 | 2025 | Trelegy Ellipta, Arexvy, Nucala |
| Neuronetics, INC. | $112.18 | 2020 | |
| Lilly USA, LLC | $47.73 | 2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $43.36 | 2025 | Korlym |
| Allergan, INC. | $26.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.94 | 2025 | Takhzyro |
| Renalytix Ai, INC. | $22.81 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Phadia US INC. | $20.95 | 2024 | Immunocap |
| Exact Sciences Corporation | $18.55 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $17.92 | 2025 | Airsupra |
| Nevro Corp. | $17.24 | 2021 | |
| Pfizer INC. | $16.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.